Abstract
Renal cell carcinoma (RCC) is the most common type of renal tumor, which has a poor prognosis. Improvements in understanding the underlying molecular biology of RCC has led to systemic treatments, which have markedly improved patient outcomes. Therefore, it is necessary and worthwhile to identify novel biomarkers for RCC. MicroRNAs (miRNAs) have been found to be important in a wide range of biological and pathological processes, including cell differentiation, migration, growth, proliferation, apoptosis and metabolism. Aberrant expression of miRNA‑130b has previously been reported in tumors, however, its role in RCC remains to be elucidated. In the present study, the upregulation of miR‑130b was observed in RCC tissues and cell lines using reverse transcription‑quantitative polymerase chain reaction analysis, which was consistent with previous microRNA profiling in RCC. Furthermore, the effects of miR‑130b on cell migration, proliferation and apoptosis were examined using a wound scratch assay, an MTT assay and flow cytometric analysis, respectively. The results demonstrated that the downregulation of miR‑130b by a synthesized inhibitor inhibited cell migration, suppressed cell proliferation and induced RCC cell apoptosis. The present study was the first, to the best of our knowledge, to suggest that miR‑130b may be a promising biomarker for diagnosis and a therapeutic target for the treatment of RCC. Further investigations are required to examine the roles and target genes of miR‑130b in RCC.
Highlights
Kidney cancer is one of the most common types of malignancy in developed countries, and is increasing in developing countries [1,2]
These results suggested that miR‐130b acts as an oncogene in Renal cell carcinoma (RCC)
The well‐known dysregulated signal transduction pathways in RCC tumorigenesis, including the anti‐oncogene, von Hippel Lindau (VHL) and oncogene, vascular endothelial growth factor (VEGF) [13]. miRNAs are a class of small non‐coding RNA, which exert their function by targeting specific genes, including hypoxia‐inducible factor, mammalian target of rapamycin, VEGF and VHL, which are key molecules involved in the initiation and development of clear cell RCC, through translation inhibition or the induction of mRNA degradation [32,33]
Summary
Kidney cancer is one of the most common types of malignancy in developed countries, and is increasing in developing countries [1,2]. Kidney cancer is more prevalent in males, and its estimated incidence and mortality rates in males are ~111,100 and 43,000 per year in developed countries [1]. Renal cell carcinoma (RCC) accounts for ~90% of all renal tumors and 3.7% of all types of cancer in adults [3,4]. Clear cell RCC, which accounts for 80% of patients with RCC, is the most aggressive histological type of RCC, which has the highest rate of metastasis and the poorest prognosis [5]. Developments in current understanding of the underlying molecular biology of renal cell carcinoma have led to systemic treatments, which have markedly improved patient outcomes [7]. It is necessary and worthwhile to identify novel biomarkers for RCC to improve diagnosis and treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
